Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma (Jun 2022)
Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (Oct 2022)
In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure (Apr 2020)
CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury (Feb 2020)
Seeding decellularized nerve allografts with adipose-derived mesenchymal stromal cells: An in vitro analysis of the gene expression and growth factors produced (Aug 2019)
Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy (Jul 2019)
Alterations in genetic and protein content of swine adipose tissue-derived mesenchymal stem cells in the Metabolic Syndrome (May 2019)
In Vivo Survival of Mesenchymal Stromal Cell-Enhanced Decellularized Nerve Grafts for Segmental Peripheral Nerve Reconstruction (Jun 2019)
Targeting Murine Mesenchymal Stem Cells to Kidney Injury Molecule-1 Improves Their Therapeutic Efficacy in Chronic Ischemic Kidney Injury (May 2018)
Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives (Feb 2017)
Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS (Nov 2016)
Preservation of epithelial progenitor cells from collagenase-digested oral mucosa during ex vivo cultivation (Nov 2016)
Adipose-derived mesenchymal stem cells from patients with atherosclerotic renovascular disease have increased DNA damage and reduced angiogenesis that can be modified by hypoxia (Sep 2016)
A Safety Study on Intrathecal Delivery of Autologous Mesenchymal Stromal Cells in Rabbits Directly Supporting Phase I Human Trials (May 2015)
Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis (Feb 2014)
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics (Jun 2013)